<PAGE>
Exhibit 1.2
Letter to CCPR holders from Steven M. Odre, Senior Vice President, General
Counsel and Secretary of the Company, dated September 22, 2000
September 22, 2000
Dear CCPR Holder:
On September 11, 2000, Meridian Venture Group, L.L.C., filed a Tender Offer
Statement on Schedule TO with the SEC relating to a tender offer by Meridian
Venture Group, L.L.C., to purchase Contractual Contingent Payment Rights arising
from the purchase of Class A interests of Amgen Clinical Partners, L.P. (the
"CCPRs").
Pursuant to the Securities Exchange Act of 1934, as amended, and the rules
and regulations thereunder, Amgen is required to provide certain information to
you regarding this tender offer. Please review Amgen's
Solicitation/Recommendation Statement on Schedule 14d-9. The
Solicitation/Recommendation Statement contains a detailed explanation of Amgen's
position on the tender offer and other important information related to the
tender offer. We urge you to read the enclosed material carefully.
If you have any questions, please contact Amgen Investor Relations at (805)
447-3352.
Sincerely,
Steven M. Odre
Senior Vice President, General Counsel
and Secretary
Enclosure
